With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.
A mixture of 4-(4-ethylpiperazin-l-yl)-aniline (1 g, 4.88 mmol), (6-chloro- pyrimidin-4-yl)-methyl-amine (1.81 g, 12.68 mmol, 1.3 eq.), and 4N HC1 in dioxane (15 ml) is heated in a sealed tube to 150C for 5h. The reaction mixture is concentrated, diluted with DCM and a saturated aqueous solution of sodium bicarbonate. The aqueous layer is separated and extracted with DCM. The organic phase is washed with brine, dried (sodium sulfate), filtered and concentrated. Purification of the residue by silica gel column chromatography (DCM/MeOH, 93:7) followed by trituration in diethyl ether affords the title compound as a white solid: ESI-MS: 313.2 [MH]+; tR= 1.10 min (gradient J); TLC: Rf = 0.21 (DCM/MeOH, 93:7)., 115619-01-7
The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; NOVARTIS AG; BERGHAUSEN, Joerg; KAPA, Prasad, Koteswara; MCKENNA, Joseph; SLADE, Joel; WU, Raeann; DU, Zhengming; WO2011/71821; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics